These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34261797)

  • 21. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
    Kerr CP; Grudzinski JJ; Nguyen TP; Hernandez R; Weichert JP; Morris ZS
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
    Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    Bellavia MC; Patel RB; Anderson CJ
    J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
    Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
    Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
    J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP; Cesario RM; Goodenow B; Shojaei F; Gillings M
    BMC Cancer; 2021 Aug; 21(1):969. PubMed ID: 34461854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted α-Therapy Using
    Ertveldt T; Krasniqi A; Ceuppens H; Puttemans J; Dekempeneer Y; Jonghe K; Mey W; Lecocq Q; Vlaeminck Y; Awad RM; Goyvaerts C; Veirman K; Morgenstern A; Bruchertseifer F; Keyaerts M; Devoogdt N; D'Huyvetter M; Breckpot K
    J Nucl Med; 2023 May; 64(5):751-758. PubMed ID: 37055223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice.
    Du WY; Masuda H; Nagaoka K; Yasuda T; Kuge K; Seto Y; Kakimi K; Nomura S
    Gastric Cancer; 2024 Sep; 27(5):971-985. PubMed ID: 38805119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy.
    Zhang MR; Fang LL; Guo Y; Wang Q; Li YJ; Sun HF; Xie SY; Liang Y
    Int J Nanomedicine; 2024; 19():3387-3404. PubMed ID: 38617801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LAG3 blockade coordinates with microwave ablation to promote CD8
    Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
    J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.
    Yang Y; Vedvyas Y; Alcaina Y; Son JY; Min IM; Jin MM
    Front Immunol; 2024; 15():1355388. PubMed ID: 38550578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Specific Antibody, Cetuximab, Enhances the
    Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
    Front Immunol; 2020; 11():591139. PubMed ID: 33281820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
    Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
    Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.